Record mula sa primary source
MateryalNaisumite ang aplikasyon
PTC bibilihin ang ST-920 Fabry gene therapy; BLA filing planado sa Q4 2026
PTC ang napiling winning bidder para bilhin ang ST-920, isang BLA-stage AAV gene therapy para sa Fabry disease, mula sa Sangamo. Plano ng kumpanya na kumpletuhin ang rolling BLA submission para sa accelerated approval sa Q4 2026, gamit ang existing rare-disease infrastructure. Ang acquisition ay nananatiling subject sa bankruptcy court approval at iba pang closing conditions na inaasahang mangyayari sa late Q3 o early Q4 2026.
Mahahalagang fact
- Na-file
- Ago 13, 2026, 11:00 AM
- Kaganapan
- Naisumite ang aplikasyon
- Direksyon
- Positibo
- Kumpanya
PTCTPTC Therapeutics- Pinagmulan
- SEC 8-K
- Kumpiyansa
- May source
- Paunang bayad
- $111 milyon
- Mga yugto
- hanggang $100 milyon
Sipi mula sa source
EX-99.1 2 tmb-20260812xex99d1.htm EX-99.1 Exhibit 99.1 PTC to Expand Rare Disease Portfolio with Acquisition of BLA-Stage ST-920 Fabry Disease Program – Planned acquisition leverages existing regulatory and commercial infrastructure and leadership's experience in Fabry therapy commercialization – – ST-920 is a one-time administered AAV gene therapy for the enzyme deficient in Fabry disease with demonstrated long-term clinical benefits and safety profile – – BLA submission expected to be completed in Q4 2026 with potential for commercial launch in 2027 – – PTC will host a conference call today, Aug. 12, at 5 p.m. ET – WARREN, N.J., Aug. 12, 2026 – PTC Therapeutics, Inc., (NASDAQ: PTCT) today announced that it was selected as the winning bidder to acquire ST-920 – a BLA-stage one-tim
Higit pa tungkol sa asset na ito
Kapansin-pansin
Ago 28, 2026
08:06 PM
PTCTPTC TherapeuticsKukunin ng PTC Therapeutics ang ST-920 AAV gene therapy para sa Fabry disease